Drug Trial Radar · NCT03720470
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
Last checked: Nov 19, 2026Latest source record: Jan 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
838
Actual
Start
Oct 29, 2018
Primary completion
Dec 27, 2019
Study completion Mar 6, 2020
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy. The efficacy of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily will be evaluated relative to placebo over 12 weeks. The efficacy of the two dosage strengths of PF-04965842 will be compared with dupilumab in terms of pruritus relief at 2 weeks. The two dosage strengths of PF-04965842 and dupilumab 300 mg injected subcutaneously once every two weeks (with a loading dose of 600 mg injected on the first day) will also be evaluated relative to placebo over 16 weeks. The safety of the investigational products will be evaluated over the duration of the study. Subjects will use non-medicated emollient at least twice a day and medicated topical therapy such as corticosteroids, calcineurin inhibitors or PDE4 inhibitors, as per protocol guidance, to treat active lesions during the study. Subjects who are randomized to receive one of the two dosage strengths of PF-04965842 will also receive placebo injectable study drug every two weeks until Week 16 and then will continue on receiving only the oral study drug for 4 weeks. Subjects who are randomized to receive dupilumab injections every two weeks will also receive oral placebo to be taken once daily until Week 16 and will then continue to receive only the oral placebo for 4 weeks. Subjects who are randomized to the placebo arms, will receive both daily oral placebo and injectable placebo every two weeks until Week 16, after which they will receive either 100 mg or 200 mg of PF-04965842 taken orally once daily for 4 weeks, dependent upon which arm they have been allocated to. Eligible subjects will have an option to enter a long-term extension study after completing 20 weeks of treatment.
Conditions
- Dermatitis
- Dermatitis, Atopic
- Eczema
- Skin Diseases
- Skin Diseases, Genetic
- Genetic Diseases, Inborn
- Skin Diseases, Eczematous
- Hypersensitivity
- Hypersensitivity, Immediate
- Immune System Diseases
Interventions
PF-04965842 100 mgDrug
PF-04965842 100 mg, administered as two tablets to be taken orally once daily as follows: 1. In the arm "PF-04965842 100 mg + Injectable Placebo followed by PF-04965842 100 mg," PF-04965842 100 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20; 2. In the arm "Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842" subjects take PF-04965842 100 mg from Week 16 to Week 20.
PF-04965842 200 mgDrug
PF-04965842 200 mg, administered as two tablets to be taken orally once daily as follows: 1. In the arm "PF-04965842 200 mg + Injectable Placebo followed by PF-04965842 100 mg," PF-04965842 200 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20; 2. In the arm "Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842" subjects take PF-04965842 200 mg from Week 16 to Week 20.
DupilumabDrug
Two subcutaneous injections of Dupilumab 300 mg as a loading dose administered on Day 1 (for a total of 600 mg) followed by one injection once every two weeks (q2w) until Week 16.
Oral PlaceboDrug
Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows: 1. In the arm "Dupilumab Injection + Oral Placebo followed by Oral Placebo," the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20; 2. In the arms "Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842" and "Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842," subjects, take Oral Placebo from Day 1 until Week 16.
Injectable PlaceboDrug
Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and a Reduction of Greater Than or Equal to (>=) 2 Points From Baseline at Week 12Time frame: Baseline (the last measurement prior to first dosing on Day 1), Week 12
- Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=75 Percent (%) Improvement From Baseline at Week 12Time frame: Baseline, Week 12
Locations
216 sites in 18 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama, LLC
Birmingham, Alabama
The University Of Alabama At Birmingham
Birmingham, Alabama
Marvel Research, LLC
Huntington Beach, California
Alliance Research Centers
Laguna Hills, California
Allergy & Asthma Care Center of Southern California
Long Beach, California
Allergy & Asthma Associates of Southern California dba Southern California Research
Mission Viejo, California
Dermatology Specialists, Inc.
Murrieta, California
MedDerm Associates
San Diego, California
Clinical Science Institute
Santa Monica, California
Synexus Clinical Research US, Inc.
Santa Rosa, California
IMMUNOe Research Centers
Centennial, Colorado
Renaissance Research and Medical Group, Inc
Cape Coral, Florida
C & R Research Services USA, Inc
Coral Gables, Florida
Florida Academic Centers Research and Education, LLC
Coral Gables, Florida
Moonshine Research Center, Inc.
Doral, Florida
Solutions Through Advanced Research, Inc.
Jacksonville, Florida
Olympian Clinical Research
Largo, Florida
Savin Medical Group LLC
Miami, Florida
Wellness Clinical Research, LLC
Miami Lakes, Florida
ForCare Clinical Research
Tampa, Florida
Research Institute of Southeast, LLC
West Palm Beach, Florida
Research Institute of the Southeast, LLC
West Palm Beach, Florida
Columbus Regional Research Institute
Columbus, Georgia
Idaho Allergy and Research
Eagle, Idaho
ASR, LLC
Nampa, Idaho
Great Lakes Clinical Trials
Chicago, Illinois
Midwest Allergy Sinus Asthma, SC
Normal, Illinois
NorthShore University HealthSystem
Skokie, Illinois
Southern Illinois University School of Medicine
Springfield, Illinois
Dundee Dermatology
West Dundee, Illinois
The Indiana Clinical Trials Center
Plainfield, Indiana
Forefront Dermatology, S.C.
Louisville, Kentucky
Meridian Clinical Research, LLC
Baton Rouge, Louisiana
Clinical Research Institute, Inc.
Minneapolis, Minnesota
Skin Laser and Surgery Specialists of NY and NJ
Hackensack, New Jersey
Forest Hills Dermatology Group
Kew Gardens, New York
Juva Skin and Laser Center
New York, New York
TrialSpark, Inc (Russell Cohen)
Oceanside, New York
Cary Dermatology Center, PA
Cary, North Carolina
PMG Research of Raleigh, LLC d/b/a PMG Research of Cary
Cary, North Carolina
Showing 40 of 216 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.